ATM mutation is associated with shorter overall survival in relapsed/advanced urothelial cancer
Journal of Clinical Oncology Mar 06, 2019
Yin M, et al. - Researchers estimated 88 cases to evaluate the prognostic values of mutations in ATM in tumors of subjects with relapsed/advanced (TxN2-3M0-1) urothelial cancer (UC) via 3 independent datasets. They observed the presence of ATM mutations in 14.8%, 11% and 6.2% of the 3 cohorts. They recorded a constant association of ATM mutations with a significantly shorter overall survival (OS) and with a poorer survival as well. Hence, they suggested ATM mutations, a negative prognostic biomarker in relapsed/advanced UC patients.Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins